Articles

Dr Vaibhav Sahai and Dr Angela Lamarca consider options for managing patients with CCA while awaiting results from biomarker testing, which can take 3 to 6 weeks. They discuss starting these patients on first-line chemotherapy and then switching appropriate patients to second-line targeted therapy, and also speak to the increased utility of next-generation sequencing in CCA.

AVBCC Co-Chair Barry Brooks describes how the AVBCC Summit is a premier opportunity to discuss the future of cancer care with some of the most knowledgable industry leaders, practitioners, pharmacists, payers, policymakers, and C-suite executives.

AVBCC Co-Chair William McGivney talks about what attendees can expect to gain from the AVBCC Summit, and why the value equation in cancer care is an issue that affects all stakeholders in the oncology space.

Watch AVBCC Co-Founder and Chairman Burt Zweigenhaft as he explains what differentiates the AVBCC Summit from other oncology meetings and why you can't afford to miss out on this unique gathering of stakeholders from all facets of the cancer care spectrum.

Dr Vaibhav Sahai discusses different approaches to molecular biomarker testing, including when to order the tests in the course of the disease, use of institutional and commercial testing facilities, and what platforms exist for testing.